ArticleJCO precision oncology2020

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases.

Alexander Andreev-Drakhlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.